Vimarsana
Biggest News Aggregation in the World

Scir L News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scir L. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scir L Today - Breaking & Trending Today

Scirocco appoint Muir Miller to bolster renewables strategy | 18 February 2021 - Vimarsana News

Scirocco appoint Muir Miller to bolster renewables strategy | 18 February 2021

18 February 2021 | 09:05am StockMarketWire.com - Energy investment company Scirocco has appointed Muir Miller as an Independent Non-executive Director with immediate effect, as part of a wider strategy to create long-term, sustainable value in European energy market. Alastair Ferguson, Chairman of Scirocco, said: ‘We welcome Muir to our Board and look forward to adding his experience to the pool of renewables experience we possess.’ Muir has two decades of senior executive experience, with particular focus on the renewable energy sector and will apply his specialist experience to support ...

Scirocco notes 'positive' developments at 14% owned Helium One's project | 18 February 2021 - Vimarsana News

Scirocco notes 'positive' developments at 14% owned Helium One's project | 18 February 2021

Scirocco notes 'positive' developments at 14% owned Helium One's project

Circassia lowers earnings breakeven point after restructuring; annual revenue falls | 12 January 2021 - Vimarsana News

Circassia lowers earnings breakeven point after restructuring; annual revenue falls | 12 January 2021

12 January 2021 | 08:19am StockMarketWire.com - Medical device company Circassia lowered its earnings breakeven point for its Niox business on margin improvements after largely completing restructuring plan. But annual revenue fell on the impact of the global lockdown. For the continuing Niox business for the year ended 31 December 2020, revenue fell to £23.9 million from £34.6 million. 'The global lockdown which commenced at the start of the second quarter significantly affected testing volumes in the clinical business and delayed studies for our research customers, the company said....